Peres Jepchirchir provisionally suspended after EPO positive before Sydney Marathon win

The marathon world has been hit by a major doping controversy after Olympic and world marathon champion Peres Jepchirchir was provisionally suspended by the Athletics Integrity Unit. The AIU action followed an out-of-competition sample that tested positive for erythropoietin, commonly known as EPO. According to the AIU, the sample was provided before Jepchirchir won the Sydney Marathon on 30 August 2026. At the time, she was in Kenya. The news is significant because the 33-year-old Kenyan has been one of the most successful and consistent women marathon runners of recent years. She won the women marathon at the Tokyo 2026 Olympics and returned to the Japanese capital to win the World Championships marathon in September 2026. She also has major marathon victories in New York in 2026, Boston in 2026, London in 2026 and now Sydney. Jepchirchir clocked two hours, 18 minutes and 31 seconds to win in Sydney. She finished more than three minutes ahead of her compatriot Irene Chepet Cheptai. The Sydney Marathon became the seventh world major in 2026, and Jepchirchir victory added another major title to her impressive career. However, the result now sits under a cloud because the sample that produced the EPO positive was taken before the race. EPO is a natural substance produced in the kidneys that stimulates the creation of new red blood cells. When injected, it can be detected in urine or blood only for a short window. It increases the number of red blood cells, which carry oxygen to the muscles. For that reason, EPO is considered a prohibited endurance-boosting substance and its use is a serious anti-doping violation. The provisional suspension means Jepchirchir cannot compete in recognised events while the case is pending. It does not mean a final finding of guilt has been made. Under anti-doping rules, she will have the right to respond, to request analysis of the B sample and to present her case at a disciplinary hearing. A final decision will come only after the full process. Jepchirchir broke the women half-marathon world record in 2026 and broke it three times in 2026. Her rise from road racing to marathon prominence made her one of the biggest names in the sport. She won the Tokyo Olympic marathon, the world marathon title and several major marathons, a rare combination of achievements. Those results are now being viewed in a different light because of the positive sample. The case also raises broader questions for the Sydney Marathon and for the Abbott World Marathon Majors series. Sydney became the seventh major in 2026, and Jepchirchir victory in 2026 was expected to raise the race profile. Instead, the event is now part of a doping story. If the violation is confirmed, her Sydney result could be annulled and she could face a long ban. If the case is not confirmed, her suspension would be lifted and she could return to competition. Kenya has a rich marathon tradition, but the country has also faced repeated doping debates. Jepchirchir has been one of the brightest faces of that tradition. Her case will put pressure on sports administrators and support systems in Kenya, and it will again focus attention on how elite athletes are tested and monitored. The AIU uses out-of-competition testing to detect athletes who may try to avoid in-competition controls. EPO is difficult to identify because it occurs naturally in the body, so anti-doping authorities use blood and urine analysis as well as the athlete biological passport. The timing of the sample in this case is important because it was collected before the Sydney race, meaning the investigation concerns the period before the competition. For now, Jepchirchir remains provisionally suspended. The next steps will depend on the B sample, her response and the disciplinary process. Until then, the marathon world waits for clarity on a case that could affect one of the sport most decorated runners and the reputation of the events she has won.